GE HealthCare Stock: Analyst Estimates & Ratings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2025
0mins
Source: NASDAQ.COM
Company Performance: GE HealthCare Technologies Inc. has a market cap of $32 billion but has underperformed the market, with stock prices declining 11.1% over the past year compared to the S&P 500's gains. Despite this, the company reported a 2.7% increase in Q1 revenue and a 12.3% rise in adjusted net income, surpassing analysts' expectations.
Analyst Ratings: The consensus rating for GEHC is "Strong Buy," with 13 out of 18 analysts recommending it as such. However, Morgan Stanley has maintained a "Hold" rating while lowering its price target, indicating mixed sentiments about the stock's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GEHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GEHC
Wall Street analysts forecast GEHC stock price to rise
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 60.640
Low
80.00
Averages
92.25
High
105.00
Current: 60.640
Low
80.00
Averages
92.25
High
105.00
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stocks Plunge Sharply, Tech Sector Hit Hard
- Market Performance: The S&P 500 Index fell by 1.04%, reaching a 1.5-week low, while the Nasdaq 100 dropped by 2.67%, reflecting investor concerns over high valuations in tech stocks, which could impact future investment decisions.
- Asian Market Impact: Japan's Nikkei Index declined by over 3%, and South Korea's Kospi fell by more than 10%, with foreign investors offloading over $2.5 billion in Kospi shares, exacerbating negative sentiment and contributing to a global market downturn.
- Divergent Manufacturing Data: The U.S. June manufacturing PMI unexpectedly rose to 55.7, surpassing expectations, indicating economic resilience; however, the Richmond Fed manufacturing survey fell to 4, suggesting challenges in the economic recovery that may influence Fed policy.
- Bond Market Reaction: In response to the sharp equity selloff, the 10-year T-note yield dropped to 4.485%, indicating increased demand for safe-haven assets, although upcoming Treasury auctions may exert upward pressure on yields.
See More
Major Rating Changes on Wall Street
- IBM Upgrade: JPMorgan upgraded IBM from Neutral to Overweight, citing a deeper analysis of its software business that suggests significant performance acceleration in 2H'26, thereby enhancing market confidence in the company's growth trajectory.
- Qiagen Upgrade: Morgan Stanley upgraded Qiagen from Equal Weight to Overweight, noting that AI-driven growth improvements and the clearing of competitive risks are expected to positively impact the life sciences sector.
- Smurfit Westrock Initiation: Deutsche Bank initiated coverage of Smurfit Westrock with a Buy rating and a $57 price target, emphasizing its high-margin operations and strong market position as catalysts for value creation in the packaging industry.
- Target Upgrade: Wolfe upgraded Target from Peer Perform to Outperform, stating that now is the optimal time to buy, as the company is poised for significant improvements driven by store resets and a new leadership team shaking up the status quo.
See More
Analysis of JAVA Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: JAVA's stock has a 52-week low of $63.67 and a high of $78.52, with the latest trade at $77.93, indicating that the stock is nearing its high point, reflecting market optimism about its future performance.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides investors with valuable insights for technical analysis, helping to assess long-term trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Liquidity Monitoring: Weekly monitoring of changes in shares outstanding for ETFs allows for the identification of those experiencing significant inflows or outflows, enabling timely adjustments to investment strategies based on market dynamics.
See More
GE HealthCare Launches MIM Contour ProtégéAI+ 2.0 for Enhanced Radiation Therapy
- FDA Approval: GE HealthCare's MIM Contour ProtégéAI+ 2.0 has received 510(k) clearance from the FDA, marking a significant advancement in radiation oncology treatment planning, which is expected to greatly enhance clinical teams' efficiency and enable faster, personalized patient care.
- Technological Innovation: The new version introduces a Magnetic Resonance Brain model and an updated CT Male Pelvis model, expanding clinical capabilities across key anatomical regions, which is anticipated to improve the precision and efficiency of radiation therapy to meet increasingly complex patient needs.
- Process Automation: MIM Contour ProtégéAI+ 2.0 minimizes user interaction by enabling automatic contouring, significantly reducing manual effort and allowing clinical teams to focus more on developing personalized treatment plans, thereby enhancing the quality of patient care.
- Market Outlook: With the rising global cancer incidence, this innovative product from GE HealthCare not only addresses the market demand for efficient radiation therapy but also strengthens its competitive position in the medical technology sector through continuous technological iterations and updates.
See More
FRT vs GEHC Stock Performance Comparison
- Price Dynamics: FRT is currently trading up approximately 0.6%, indicating a degree of market resilience, which may attract investor attention despite overall market uncertainty.
- GEHC Decline: GEHC's stock is down about 1%, reflecting market concerns over its future growth potential, which could impact investor confidence and lead to capital outflows.
- Market Comparison: On the same trading day, the contrasting stock movements of FRT and GEHC highlight FRT's relative strength in the current economic environment, potentially signaling a shift in investor preference.
- Investor Sentiment: The rise of FRT alongside the decline of GEHC may influence investor asset allocation decisions, prompting a reassessment of their investment ratios in these two stocks.
See More
UBS Upgrades GE HealthCare to Neutral Amid Stock Decline
- Rating Upgrade: UBS upgraded GE HealthCare from Sell to Neutral and lowered its price target from $75 to $69, reflecting a reassessment of the company's stock valuation as shares trade near a 52-week low of $64.
- Stock Decline Reasons: GE HealthCare's stock fell approximately 30% following its Q1 earnings report, primarily due to disappointing results with $5.1 billion in quarterly revenue and an adjusted EPS of $0.99, missing the expected $1.05.
- Cost Pressures: Management highlighted that a supplier recall exacerbated margin pressures stemming from rising costs related to memory chips, oil prices, and freight, leaving little room to offset these headwinds in the short term.
- Long-Term Growth Confidence: Despite short-term challenges, GE HealthCare's leadership reaffirmed its long-term growth trajectory at the Bank of America Global Healthcare Conference, anticipating that cost initiatives, pricing actions, and new product launches will help restore margin improvement.
See More
U.S. Stocks Plunge Sharply, Tech Sector Hit Hard
- Market Performance: The S&P 500 Index fell by 1.04%, reaching a 1.5-week low, while the Nasdaq 100 dropped by 2.67%, reflecting investor concerns over high valuations in tech stocks, which could impact future investment decisions.
- Asian Market Impact: Japan's Nikkei Index declined by over 3%, and South Korea's Kospi fell by more than 10%, with foreign investors offloading over $2.5 billion in Kospi shares, exacerbating negative sentiment and contributing to a global market downturn.
- Divergent Manufacturing Data: The U.S. June manufacturing PMI unexpectedly rose to 55.7, surpassing expectations, indicating economic resilience; however, the Richmond Fed manufacturing survey fell to 4, suggesting challenges in the economic recovery that may influence Fed policy.
- Bond Market Reaction: In response to the sharp equity selloff, the 10-year T-note yield dropped to 4.485%, indicating increased demand for safe-haven assets, although upcoming Treasury auctions may exert upward pressure on yields.
See More
Major Rating Changes on Wall Street
- IBM Upgrade: JPMorgan upgraded IBM from Neutral to Overweight, citing a deeper analysis of its software business that suggests significant performance acceleration in 2H'26, thereby enhancing market confidence in the company's growth trajectory.
- Qiagen Upgrade: Morgan Stanley upgraded Qiagen from Equal Weight to Overweight, noting that AI-driven growth improvements and the clearing of competitive risks are expected to positively impact the life sciences sector.
- Smurfit Westrock Initiation: Deutsche Bank initiated coverage of Smurfit Westrock with a Buy rating and a $57 price target, emphasizing its high-margin operations and strong market position as catalysts for value creation in the packaging industry.
- Target Upgrade: Wolfe upgraded Target from Peer Perform to Outperform, stating that now is the optimal time to buy, as the company is poised for significant improvements driven by store resets and a new leadership team shaking up the status quo.
See More
Analysis of JAVA Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: JAVA's stock has a 52-week low of $63.67 and a high of $78.52, with the latest trade at $77.93, indicating that the stock is nearing its high point, reflecting market optimism about its future performance.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides investors with valuable insights for technical analysis, helping to assess long-term trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Liquidity Monitoring: Weekly monitoring of changes in shares outstanding for ETFs allows for the identification of those experiencing significant inflows or outflows, enabling timely adjustments to investment strategies based on market dynamics.
See More
GE HealthCare Launches MIM Contour ProtégéAI+ 2.0 for Enhanced Radiation Therapy
- FDA Approval: GE HealthCare's MIM Contour ProtégéAI+ 2.0 has received 510(k) clearance from the FDA, marking a significant advancement in radiation oncology treatment planning, which is expected to greatly enhance clinical teams' efficiency and enable faster, personalized patient care.
- Technological Innovation: The new version introduces a Magnetic Resonance Brain model and an updated CT Male Pelvis model, expanding clinical capabilities across key anatomical regions, which is anticipated to improve the precision and efficiency of radiation therapy to meet increasingly complex patient needs.
- Process Automation: MIM Contour ProtégéAI+ 2.0 minimizes user interaction by enabling automatic contouring, significantly reducing manual effort and allowing clinical teams to focus more on developing personalized treatment plans, thereby enhancing the quality of patient care.
- Market Outlook: With the rising global cancer incidence, this innovative product from GE HealthCare not only addresses the market demand for efficient radiation therapy but also strengthens its competitive position in the medical technology sector through continuous technological iterations and updates.
See More
FRT vs GEHC Stock Performance Comparison
- Price Dynamics: FRT is currently trading up approximately 0.6%, indicating a degree of market resilience, which may attract investor attention despite overall market uncertainty.
- GEHC Decline: GEHC's stock is down about 1%, reflecting market concerns over its future growth potential, which could impact investor confidence and lead to capital outflows.
- Market Comparison: On the same trading day, the contrasting stock movements of FRT and GEHC highlight FRT's relative strength in the current economic environment, potentially signaling a shift in investor preference.
- Investor Sentiment: The rise of FRT alongside the decline of GEHC may influence investor asset allocation decisions, prompting a reassessment of their investment ratios in these two stocks.
See More
UBS Upgrades GE HealthCare to Neutral Amid Stock Decline
- Rating Upgrade: UBS upgraded GE HealthCare from Sell to Neutral and lowered its price target from $75 to $69, reflecting a reassessment of the company's stock valuation as shares trade near a 52-week low of $64.
- Stock Decline Reasons: GE HealthCare's stock fell approximately 30% following its Q1 earnings report, primarily due to disappointing results with $5.1 billion in quarterly revenue and an adjusted EPS of $0.99, missing the expected $1.05.
- Cost Pressures: Management highlighted that a supplier recall exacerbated margin pressures stemming from rising costs related to memory chips, oil prices, and freight, leaving little room to offset these headwinds in the short term.
- Long-Term Growth Confidence: Despite short-term challenges, GE HealthCare's leadership reaffirmed its long-term growth trajectory at the Bank of America Global Healthcare Conference, anticipating that cost initiatives, pricing actions, and new product launches will help restore margin improvement.
See More
